Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey
Poor HRQoL and high retreatment rates indicate a need for new therapy options in patients with MM in Japan. These findings may guide healthcare policies and clinical practice in Japan.
Authors
- Yasuhiro Yasutomi (ORCID: https://orcid.org/0009-0000-1853-974X)
- Simon McNamara (ORCID: https://orcid.org/0000-0003-1082-118X)
- Emily Luke (ORCID: https://orcid.org/0000-0002-9618-3635)
- Amanda Ribbands (ORCID: https://orcid.org/0000-0001-9819-8737)
Institutions
- Age UK (GB)
- Adelphi Group (United Kingdom) (GB)
- GlaxoSmithKline (Japan) (JP)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1080/14796694.2025.2460419
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- GlaxoSmithKline
- GlaxoSmithKline Japan